Circadian and time-dependent variability in tacrolimus pharmacokinetics

Fundamental and Clinical Pharmacology

Volumn 21, Issue 2, 2007, Pages 191-197

  Park, Sung In ^a   Felipe, Claudia R ^a   Pinheiro Machado, Paula G ^a   Garcia, Riberto ^a   Tedesco Silva Jr , Helio ^a   Medina Pestana, Jose O ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Circadian; Immunosuppression; Kidney transplant; Pharmacokinetic; Tacrolimus; Time dependent

Indexed keywords

AZATHIOPRINE; METHYLPREDNISOLONE; OKT 3; PREDNISONE; TACROLIMUS;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOCHEMISTRY; BLOOD SAMPLING; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG DOSE REDUCTION; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; HEMATOLOGY; HUMAN; KIDNEY TRANSPLANTATION; LIVING DONOR; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AREA UNDER CURVE; CIRCADIAN RHYTHM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TACROLIMUS; TIME FACTORS;

EID: 33947690164     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2007.00468.x     Document Type: Article

References (21)

1. Staatz C.E., Tett S.E. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin. Pharmacokinet. (2004) 43 623-653.
2. Jusko W.J., Thomson A.W., Fung J. et al. Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther. Drug Monit. (1995) 17 606-614.
3. Lemmer B. Chronopharmacokinetics: implications for drug treatment. J. Pharm. Pharmacol. (1999) 51 887-890.
4. Min D.I., Chen H.Y., Fabrega A. et al. Circadian variation of tacrolimus disposition in liver allograft recipients. Transplantation (1996) 62 1190-1192.
5. Min D.I., Chen H.Y., Lee M.K., Ashton K., Martin M.F. Time-dependent disposition of tacrolimus and its effect on endothelin-1 in liver allograft recipients. Pharmacotherapy (1997) 17 457-463.
6. Tada H., Satoh S., Iinuma M. et al. Chronopharmacokinetics of tacrolimus in kidney transplant recipients: occurrence of acute rejection. J. Clin. Pharmacol. (2003) 43 859-865.
7. Felipe C.R., Silva H.T., Machado P.G., da Silva R.G., Moreira S.R., Pestana J.O. The impact of ethnic miscegenation on tacrolimus clinical pharmacokinetics and therapeutic drug monitoring. Clin. Transplant. (2002) 16 262-272.
8. Kuypers D.R., Claes K., Evenepoel P. et al. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients. Clin. Pharmacokinet. (2004) 43 741-762.
9. Bekersky I., Dressler D., Mekki Q.A. Effect of low- and high-fat meals on tacrolimus absortion following 5 mg single oral doses to healthy human subjects. J. Clin. Pharmacol. (2001) 41 176-186.
10. Sheiner L.B., Beal S.L. Some suggestions for measuring predictive performance. J. Pharm. Biopharmacol. (1981) 9 503-512.
11. Kung L., Batiuk T.D., Palomo-Pinon S., Noujaim J., Helms L.M., Halloran P.F. Tissue distribution of calcineurin and its sensitivity to inhibition by cyclosporine. Am. J. Transplant. (2001) 1 325-333.
12. Glander P., Hambach P., Braun K.P. et al. Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients. Int. J. Clin. Pharmacol. Ther. (2003) 41 470-476.
13. Asokan V.S., Sweny P., Varghese Z., Moorhead J.F., Fernando O.N. Comparison of oral and intravenous cyclosporin A in kidney transplants. Transplant. Proc. (1987) 19 1717-1718.
14. Tarantino A., Passerini P., Campise M. et al. Is cyclosporine in renal-transplant recipients more effective when given twice a day than in a single daily dose? Transplantation (2004) 78 675-680.
15. Sampaio E.L., Park S.I., Felipe C.R., Silva H.T., Jr, Pestana J.O. Impact of cyclosporine dosing frequency on graft function and survival after the conversion from sandimmun to neoral in stable kidney transplanted patients. Transplant. Proc. (2002) 34 3153-3161.
16. Scholten E.M., Cremers S.C., Schoemaker R.C. et al. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int. (2005) 67 2440-2447.
17. Jorgensen K., Povlsen J., Madsen S. et al. C2 (2-h) levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal-transplant patients. Nephrol. Dial. Transplant. (2002) 17 1487-1490.
18. Kimikawa M., Kamoya K., Toma H., Teraoka S. Effective oral administration of tacrolimus in renal transplant recipients. Clin. Transplant. (2001) 15 324-329.
19. Braun F., Schutz E., Peters B. et al. Pharmacokinetics of tacrolimus primary immunosuppression in kidney transplant recipients. Transplant. Proc. (2001) 33 2127-2128.
20. Wong K.M., Shek C.C., Chau K.F., Li C.S. Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients. Am. J. Kid. Dis. (2000) 35 660-666.
21. Armendariz Y., Pou L., Cantarell C., Lopez R., Perello M., Capdevila L. Evaluation of a limited sampling strategy to estimate area under the curve of tacrolimus in adult renal transplant patients. Ther. Drug Monit. (2005) 27 431-434.